当前位置: X-MOL首页全球导师 国内导师 › 刘代红

个人简介

教育经历 1985.7-1990.7:大连医科大学医疗系英文班医学学士 1992.9-1995.7:北京大学血液病研究所临床技能型研究生医学硕士1999.7-2001.9:德国海德堡大学医学博士(M.D.) 工作经历 1990.8-1992.8:沈阳医学院附属二院普通内科住院医师 1995.8-1999.6:北京大学人民医院住院医师、大内科住院总医师、主治医师 2001.10-2014.9:北京大学主治医师、副主任医师、主任医师、副教授 2013.12:博士生导师 2014.9-2016.12:解放军总医院血液科主任医师、副教授 2016.12-至今:解放军总医院血液科主任医师、教授 承担课题项目: 1.国家临床重点专科军队建设项目(临床专业):2016.01-2018.12 2.中国抗癌协会继教育科技服务部项目:2015-2016,早期分子学反应在慢性髓系白血病患者酪氨酸激酶抑制剂治疗中的预后指导意义的研究 3.中国抗癌协会:同胞全合的异基因造血干细胞移植中福达拉滨替代改良BUCy方案中环磷酰胺的随机对照研究 4.985项目,血液恶性肿瘤的诊治,985-2-115-112,2008-12-1~2010-12-1 5.863计划,HLA不合造血干细胞移植方法的建立与完善,2006AA02Z4AO,2006-12-1~2008-12-31 6.国家杰出青年科学基金,血液与淋巴系统内科学,30725038,2008-1-1~2011-12-1

研究领域

1.重症/恶性血液病的诊治 2.造血干细胞移植

近期论文

查看导师最新文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

1.LuWang,Dai-HongLiu.TyrosineKinaseInhibitorforTreatmentofAdultAllogeneicHematopoieticStemCellTransplantationCandidatewithPhiladelphia-PositiveAcuteLymphoblasticLeukemia.ChineseMedicalJournal.January20,2017(130:2) 2.LiHH,LiF,GaoCJ,HuangWR,BoJ,DouLP,WangLL,JingY,WangL,LiWJ,YuL,LiuDH.SimilarincidenceofsevereacuteGVHDandlessseverechronicGVHDinPBSCTfromunmanipulated,haploidenticaldonorscomparedwiththatfrommatchedsiblingdonorsforpatientswithhaematologicalmalignancies.BrJHaematol.2016Oct7. 3.HuangWR,LiHH,GaoCJ,BoJ,LiF,DouLP,WangLL,JingY,WangL,LiuDH,YuL.Haploidentical,unmanipulatedG-CSF-primedperipheralbloodstemcelltransplantationforhigh-riskhematologicmalignancies:anupdate.BoneMarrowTransplant.2016Jun20. 4.LiuDH,XuLP,ZhangXH,WangY,YanCH,WangJZ,WangFR,SunYQ,JiY,ZhangYY,LiuKY,HuangXJ.SubstitutionofcyclophosphamideinthemodifiedBuCyregimenwithfludarabineisassociatedwithincreasedincidenceofseverepneumonia:aprospective,randomizedstudy.IntJHematol.2013Dec;98(6):708-15. 5.LiuDH,XuLP,LiuKY,WangY,ChenH,HanW,ZhangXH,YanCH,ZhangYY,WangJZ,ChenYH,WangFR,HuangXJ.Long-termoutcomesofunmanipulatedhaploidenticalHSCTforpaediatricpatientswithacuteleukaemia.BoneMarrowTransplant.2013Jul29. 6.YanCH,LiuDH,LiuKY,XuLP,LiuYR,ChenH,HanW,WangY,QinYZ,HuangXJ.Riskstratification-directeddonorlymphocyteinfusioncouldreducerelapseofstandard-riskacuteleukemiapatientsafterallogeneichematopoieticstemcelltransplantation.Blood.2012Apr5;119(14):3256-62. 7.YuWang#,MD;Dai-HongLiu#,MD;Kai-YanLiu,MD;Lan-PingXu,MD;Xiao-HuiZhang,MD;WeiHan,MD;HuanChen,MD;Yu-HongChen,MD;Feng-RongWang,MD;Jing-ZhiWang,MD;Yu-QianSun,MD;Xiao-JunHuang,MD.Long-termfollow-upofhaploidenticalhematopoieticstemcelltransplantationwithoutin-vitroT-cell-depletionforthetreatmentofleukemia:nineyearsofexperienceatasinglecenter.Cancer.2013Mar1;119(5):978-85. 8.LiuDH,ZhaoXS,ChangYJ,LiuYK,XuLP,ChenH,HanW,ChenYH,WangY,HuangXJ.TheImpactofGraftCompositiononClinicalOutcomesinPediatricPatientsUndergoingUnmanipulatedHLA-Mismatched/HaploidenticalHematopoieticStemCellTransplantation.PediatrBloodCancer.2011Jul15;57(1):135-41. 9.Dai-HongLiu,Xiao-JunHuang,Kai-YanLiu,Lan-PingXu,Yu-HongChen,YuWang,WeiHan,HuanChen.Thesafetyofrecombinanthumanthrombopoietininadultsafterrelatedhaploidenticalhematopoieticstemcelltransplantation,Apilotstudy.ShortCommunication.ClinicalDrugInvestigation.2011,31(1):1-7. 10.DaihongLiu,ChenhuaYan,LanpingXuetal.Diarrheaduringtheconditioningregimeniscorrelatedwiththeoccurrenceofsevereacutegraft-versus-hostdiseasethroughsystemicreleaseofinflammatorycytokines.BiolBloodMarrowTransplant.2010,16:1567-1575.

学术兼职

1.全军医学科委会血液专业委员会常委兼秘书长 2.北京医学会血液分会常委 3.中国医药教育协会感染疾病专业委员会常委 4.中国免疫学会血液免疫分会委员 5.中华医学会血液学分会移植学组委员

推荐链接
down
wechat
bug